Search for Stocks /

Themis Medicare Q3 FY26: PAT Up 1,843%, Revenue Down 4%, Debt ₹96 Cr – Turnaround or Temporary Magic Trick?


1. At a Glance – Smallcap Pharma With Big Mood Swings

Themis Medicare Ltd is currently trading at ₹90.6 with a market cap of ₹835 crore. In the last 3 months, the stock has politely declined 16.6%, and over one year it has erased nearly 48.2% of shareholder optimism. Ouch.

Now comes the twist.

Q3 FY26 revenue stands at ₹90.1 crore (down 3.9% YoY), but PAT exploded to ₹10.09 crore versus ₹0.52 crore last year. That’s a 1,843% jump. EPS moved from ₹0.06 to ₹1.10. Suddenly, the company that posted a TTM loss of ₹16.6 crore is smiling again.

ROCE is 10.4%. ROE is 7.65%. Debt stands at ₹95.6 crore. OPM (TTM) is negative at -3.33%. Interest coverage is -0.67.

So what exactly is happening here?
Is this a genuine turnaround… or just a quarter wearing makeup?

Let’s dissect this like a pharma lab report.


2. Introduction – The Comeback Kid (Or Temporary Recovery Patient?)

Themis Medicare is not a startup. It was incorporated in 1969. That means this company has survived license raj, pharma price controls, GST, pandemics, and multiple government regimes.

It manufactures antiseptics, anti-TB, anti-malarial, anti-cholesterol, and pain management drugs. Basically, if you’re sick in India, Themis probably has something for you.

But FY25 wasn’t pretty.

Revenue growth (3-year): 1%
Profit growth (3-year): -25%
TTM PAT: -₹17 crore
TTM EPS: -₹1.88

And yet, Q3 FY26 suddenly shows profitability.

Management says disruption in a significant business line continued. Matter under regulatory review. Positive development expected soon.

Whenever a pharma company says “regulatory matter under review,” investors usually start sweating.

But here’s the question:

Is Q3 the start of operational stability?
Or is it just one clean quarter in an otherwise messy year?


3. Business Model – WTF Do They Even Do?

Themis operates in three primary buckets:

1. Hospital Business (38% of FY25 revenue)

Critical care, intensive care, institutional sales, exports.
They want to become leaders in anesthesia and critical care.

2. Trade Business (20%)

Pharma, ortho, gynecology

Read Full 16 Point breakdown. Continue reading →
Members get full access to every article.
Become a member
Already a member? Log in
Read Full 16 Point breakdown. Continue reading →